Dr Gerry Dawson – Chief Scientific Officer, P1vital
Dr Dawson has considerable experience in the discovery and development of novel drugs for CNS disorders. Prior to co-founding P1vital, he was Senior Director and Head of In-Vivo Neuroscience at Merck's Neuroscience Research Centre. He coordinated both clinical and pre-clinical efforts in the areas of cognition and cognitive impairment and addiction and directed project teams responsible for drug development to the end of Phase IIB.

Dr Colin Dourish – Chief Executive Officer, P1vital
Dr Dourish has a successful track record in CNS drug discovery and drug development in both major pharmaceutical and biotechnology companies. Prior to co-founding P1vital, he was Senior Vice President Research and CSO of Vernalis Group plc, Research Director and co-founder of Cerebrus Limited, Director of Neuropharmacology at Wyeth Research and Section Head at Merck & Co.

Advisors include:

Professor Bill Deakin - Department of Psychiatry, University of Manchester
Professor Deakin has been Professor of Psychiatry at the University of Manchester since 1990. His research interests are in developing new treatments for depression and schizophrenia based on imaging and other investigations of normal and pathological neurotransmitter function, particularly of the serotonin and glutamate systems in humans.

Professor Guy Goodwin - Department of Psychiatry, University of Oxford
Professor Goodwin has been W A Handley Professor of Psychiatry at the University of Oxford since 1996. His research interests are in the treatment of bipolar disorder and the application of neuroscience in understanding the neurobiology of mood disorder and developing new treatments.

Professor Catherine Harmer - Department of Psychiatry, University of Oxford
Catherine Harmer is a Professor of Cognitive Neuroscience and Head of the Psychopharmacology and Emotion Research laboratory at the University Department of Psychiatry in Oxford. Her interests focus on the neuropsychology of antidepressant and anxiolytic drug action and in the development of early biomarker tests of drug efficacy.

Professor Robin G Morris - Clinical Neuropsychology, King's College Hospital, London
Professor Morris is a consultant neuropsychologist at King's College Hospital, where he is head of the Clinical Neuropsychology Department. His main interests are in the neuropsychology of memory and also of executive functioning. He has conducted research on a range of patients with neuropsychological disorders, including those with focal brain damage, schizophrenia, and Alzheimer's disease.

Professor David Nutt - Neuropsychopharmacology, Imperial College London
Professor Nutt is the Edmond J Safra Chair in Neuropsychopharmacology at Imperial College London. His research interests are in the psychopharmacology of anxiety, addiction and insomnia.